People · Operator
Named in public records as an officer, director or promoter · active 2010–2022 · Biotechnology, Other Health Care, Telecommunications, Software / Tech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Tobira Therapeutics, Inc. | — | Biotechnology | Series A | $23.2M | $513.3M | 2010 |
| Pure Life Renal, Inc. | — | Other Health Care | Series A | $10.5M | $211.9M | 2014 |
| TRAXyL, Inc. | — | Telecommunications | Seed | $2.1M | $23.3M | 2022 |
| Sophia Technologies Ltd | — | Software / Tech | Pre-Seed | $525K | $8.6M | 2022 |
Daniel Turner at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Daniel Turner on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Patrick Heron | 1 | 11 |
| Brian Halak | 1 | 10 |
| James Sapirstein | 1 | 7 |
| Allen Moseley | 1 | 6 |
| Jeff Fernandez | 1 | 4 |
| Laurent Fischer | 1 | 4 |
| Howard Palefsky | 1 | 4 |
| Stefano Ciampolini | 1 | 3 |
| Eckard Weber | 1 | 3 |
| Carol Brosgart | 1 | 3 |
| Stephen Carter | 1 | 3 |
| Stefano Sola | 1 | 2 |
| Orestes Lugo | 1 | 2 |
| McClelland Spence | 1 | 1 |
| Melissa McBride | 1 | 1 |
| Kathleen McGowan | 1 | 1 |
| Michael Kamdar | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.